Global HIV Vaccines Market Size By Type (Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia), By Antibiotics (Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment), By Geographic Scope And Forecast

HIV Vaccines Market Size And Forecast

HIV Vaccines Market size was valued at USD 350.01 Million in 2024 and is projected to reach USD 568.92 Million by 2032, growing at a CAGR of 6.24% from 2026 to 2032.

The immune system of the body can be boosted using the vaccine, which serves the protection against disease and infection. When the immune system fails to respond to HIV, it generates antibodies to slow the spread, it doesn't stop. Generally, HIV vaccines are made using weakened or killed viruses. HIV mutates quickly, and the vaccine targets the viruses in one form, the change in the virus results in vaccine failure. However, antiretroviral drugs anticipated for HIV, preventing HIV infection is still a primary goal. The Global HIV Vaccines Market report provides a holistic evaluation of the market. The report thoroughly analyzes important segments, trends, drivers, restraints, competitive landscape, and factors that play a substantial role in the market.

Global HIV Vaccines Market Definition

Worldwide, around 35 million people currently are infected with HIV, about 30 million people died due to AIDS infection since the beginning of the epidemic. There is no human example of clearing HIV infections naturally. HIV makes copies of it very quickly, different types of HIV exist in today's world, new types of viruses continue to rise. Many scientists are trying to understand the specific ways of the immune system which need to respond against HIV infection. Vaccines are among the foremost powerful and cost-effective disease prevention tools. The vaccine that could prevent HIV infection or stop the development of the disease would greatly support the fight against this disease.

Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio, and have gradually reduced the incidence of infectious diseases like measles and pertussis across the world. However, the question arises whether the HIV vaccine should be developed for a single strain or should be designed for varied strain structures. The whole aim is to provide better medication for the eradication of this virus by any means. There are also questions that arise about how an HIV vaccine would protect the individuals and the vaccine might not be able to prevent the infections, but stop or delay progression to diseases, or can simply reduce the infectiousness of people who are infected with HIV.

HIV prevention education and counseling are important factors to be discussed in vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral hindrance programs. The successful development of a preventive HIV vaccine positively depends upon the involvement of both the private and public sectors across the world. Currently, no government or company has the resources and encouragement to take on the initiative of developing an HIV vaccine alone. Within the public sector, the development of the HIV vaccine is necessary for several different agencies, including concerns in health, economic development, and international development.

Global HIV Vaccines Market Overview

The main factor which contributes to fueling the market growth is the growing prevalence of HIV infection. Additionally, the increasing awareness among the population regarding the infection is another factor propelling a positive outlook on the growth of the market. Moreover, the continuous expenditure on research and development activities for the development of the most effective vaccination is driving market growth. However, the expense related to the vaccines and frequent trial failure can decline the market growth.

Some of the trends in the market include the development of antiretroviral therapy as a long-acting suppression (ATLAS) is an injectable formulation that has now entered the market and has increased the standard of care compared to the other drugs. It acts as an alternative option for the existing HIV drugs.

One of the driving factors is the increasing number of new product launches and rising drug approvals to boost growth. The growing emphasis on the research and development of HIV drugs has led to new drug innovations such as Gilead Sciences, VIIV healthcare, and many more. Furthermore, many companies are involved in strategic collaborations and new medications worldwide.

One of the restraining factors is a lack of access to treatment and unawareness of HIV infection which may hinder the growth. Despite many advancements in research and development and improved scientific understanding, many people infected with HIV do not have access to timely treatment. This infection still has no treatment available. Additionally, many people are still unaware of this infection. A study conducted by BioMed Central Ltd. reported that amongst the 478 participants, one-third of the participants were unaware of it, this is the reason which may hinder the growth of the market.

Global HIV Vaccines Market Segmentation Analysis

The Global HIV Vaccines Market is segmented on the basis of Type, Antibiotics, And Geography.

HIV Vaccines Market, By Type

• Pyogenic Paronychia
• Chronic Paronychia
• Candidal Paronychia
• Acute Paronychia
• Others

Based on Type, The market is bifurcated into Pyogenic Paronychia, Chronic Paronychia, Candidal Paronychia, Acute Paronychia, and Others.

HIV Vaccines Market, By Antibiotics

• Dicloxacillin
• Fusidic Acid Ointment
• Gentamicin Ointment
• Mupirocin Ointment
• Others

Based on Antibiotics, The market is bifurcated into Dicloxacillin, Fusidic Acid Ointment, Gentamicin Ointment, Mupirocin Ointment, and Others.

HIV Vaccines Market, By Geography

• North America
• Europe
• The Asia Pacific
• Rest of the world

Based on Regional Analysis, The Global HIV Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Europe is expected to be the largest market during the forecast period. Due to the increase in HIV cases and the presence of a large number of HIV companies in the region. The rising strategic collaborations amongst the European Companies will improve drug availability, which will support the growth of the market.

Key Players

The "Global HIV Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are VIIV healthcare, Gilead Sciences, Inc, GlaxoSmithKline plc, Merck Sharp & Dohme Corp., AbbVie Inc, Mylan N.V, and many more. The competitive landscape section includes key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally.

Key Developments

• March 2021, Gilead Sciences Inc and Merck announced a collaboration agreement to co-develop and commercialize long-acting treatments for HIV. The companies plan to combine Gilead's investigational capsid inhibitor Lenacapavir and Merck's investigational nucleoside reverse translocation inhibitor to develop a two-drug regimen for HIV.
• January 2021, VIIV Healthcare received U.S FDA approval for Cabenuva, an injection indicated for the treatment of human immunodeficiency virus type 1 (HIV) for adults.